Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus CETIRIZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus CETIRIZINE.
ACTIDIL vs Cetirizine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Cetirizine is a selective second-generation H1-receptor antagonist that inhibits histamine release from mast cells and basophils, thereby reducing allergic symptoms.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
10 mg orally once daily; 5 mg orally once daily for mild symptoms
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Clinical Note
moderateCetirizine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Cetirizine is combined with Fluticasone propionate."
Clinical Note
moderateLevocetirizine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Levocetirizine."
Clinical Note
moderateLevocetirizine + Cyclosporine
Terminal elimination half-life is approximately 8.3 hours in healthy adults; extended to 20 hours in elderly and patients with renal impairment
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal (60% unchanged in urine); minor biliary/fecal (10%)
Category C
Category A/B
Antihistamine
Antihistamine
"The metabolism of Cyclosporine can be decreased when combined with Levocetirizine."